RYBREVANT®▼ (amivantamab) in combination with chemotherapy
Approval is supported by the Phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease ...
Read moreApproval is supported by the Phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease ...
Read moreEvorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany to host ...
Read more— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and ...
Read moreDIH Class A Common Stock to begin trading on the Nasdaq Global Market under ticker “DHAI”DIH Warrants to Purchase Class ...
Read morePlease read the full announcement in PDF
Read moreIRVINE, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. (“Mobix Labs” or the “Company”), a fabless semiconductor company developing ...
Read moreData update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype non-small cell lung cancer ...
Read moreInavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination ...
Read moreFirst dose-escalation results for REGN5668 (MUC16xCD28), a costimulatory bispecific, in combination with Libtayo® (cemiplimab) showed encouraging initial activity in patients ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.